COMMUNIQUÉS West-GlobeNewswire

UroGen Pharma Announces Oral Presentation at Society of Urologic Oncology (SUO) Annual Meeting
27/11/2017
Principal Investigator Seth Lerner, M.D., to present design overview of ongoing Phase 3 OLYMPUS trial of MitoGel™ for the treatment of Low-Grade UTUC and data highlights from recently completed compassionate use program [...]
3D Signatures Inc. Announces Non-Brokered Private Placement to Raise $1,500,000 and Updates Previously Announced Brokered Private Placement
27/11/2017
NOT FOR DISTRIBUTION TO U.S. NEWSWIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES TORONTO, Nov. 27, 2017 (GLOBE NEWSWIRE) -- 3D Signatures Inc. (TSX-V: DXD ) (OTCQB:TDSGF) (FSE:3D0) (the " Company " or " 3DS ") [...]
T2 Biosystems to Attend the Global Mizuho Investor Conference
27/11/2017
LEXINGTON, Mass., Nov. 27, 2017 (GLOBE NEWSWIRE) -- T2 Biosystems, Inc. (NASDAQ: TTOO ), a leader in the development of innovative diagnostic products for critical unmet needs in healthcare, today announced that John [...]
Eloxx Pharmaceuticals Announces First Patient Dosed in Phase 1b Clinical Trial
27/11/2017
Lead molecule targets genetic nonsense mutation in rare diseases Dose escalating study to enroll 36 subjects Data expected in the fourth quarter of 2018 SAN DIEGO and REHOVOT, Israel and BOSTON, Nov. 27, 2017 (GLOBE [...]
PositiveID Corporation to Present at the LD MICRO “Main Event” Investor Conference on December 6th
27/11/2017
DELRAY BEACH, Fla., Nov. 27, 2017 (GLOBE NEWSWIRE) -- PositiveID Corporation (“PositiveID” or “Company”) (OTC:PSID), a life sciences company focused on detection and diagnostics, announced today that its Chairman and [...]
iCAD’s PowerLook® Tomo Detection Experiences Growing Adoption
27/11/2017
Company to Showcase Innovative Mammography Artificial Intelligence Solution at RSNA 2017 CHICAGO, Nov. 27, 2017 (GLOBE NEWSWIRE) -- RSNA 2017 -- iCAD, Inc. (NASDAQ: ICAD ), a global leader in medical technology [...]
Inovio Pharmaceuticals SynCon® TERT Cancer Immunotherapy Combined with Checkpoint Inhibitor Synergistically Shrinks Tumor and Improves Survival in Preclinical Tumor Model
27/11/2017
PLYMOUTH MEETING, Pa., Nov. 27, 2017 (GLOBE NEWSWIRE) -- Inovio Pharmaceuticals, Inc. (NASDAQ: INO ) demonstrated the synergistic effect of combining Inovio’s TERT (telomerase reverse transcriptase) cancer immunotherapy [...]
Golden Leaf Secures Cultivation License From Health Canada For State-of-the-Art Ontario Grow Facility
27/11/2017
PORTLAND, Ore., Nov. 27, 2017 (GLOBE NEWSWIRE) -- Golden Leaf Holdings Ltd. (“GLH” or the “Company”) (CSE:GLH) (OTCQB:GLDFF), a leading cannabis oil solutions company and dispensary operator built around recognized [...]
Cancer Genetics Appoints Renowned Biotech Entrepreneur Dr. Thomas F. Widmann to its Board of Directors
27/11/2017
RUTHERFORD, N.J., Nov. 27, 2017 (GLOBE NEWSWIRE) -- Cancer Genetics, Inc. (Nasdaq: CGIX ), a leader in enabling precision medicine for oncology through molecular markers and diagnostics, today announced the appointment [...]
Intra-Cellular Therapies to Participate at the 29th Annual Piper Jaffray Healthcare Conference
27/11/2017
NEW YORK, Nov. 27, 2017 (GLOBE NEWSWIRE) -- Intra-Cellular Therapies, Inc. (Nasdaq: ITCI ), a biopharmaceutical company focused on the development of therapeutics for central nervous system ("CNS") disorders, today [...]
Medovex Corporation Submits IDE with the Food and Drug Administration for its DenerveX System
27/11/2017
ATLANTA, Nov. 27, 2017 (GLOBE NEWSWIRE) -- Medovex Corporation (NASDAQ: MDVX ) ("Medovex" or the "Company"), the developer of the DenerveX® System, a new and novel device designed for enduring relief of Facet Joint [...]
aTyr Pharma Doses First Subjects in Phase 1 Trial of iMod.Fc (ATYR1923)
27/11/2017
– Second Physiocrine-based therapeutic candidate enters the clinic – – Top-line data expected in 2Q 2018 – – iMod.Fc (ATYR1923) to target interstitial lung diseases with an immune component – SAN DIEGO, Nov. 27, 2017 ( [...]
Novo Nordisk A/S - Share repurchase programme
27/11/2017
Bagsværd, Denmark, 27 November 2017 - On 1 November 2017, Novo Nordisk initiated a share repurchase programme in accordance with Article 5 of Regulation No. 596/2014 of the European Parliament and Council of 16 April [...]
Avadel Pharmaceuticals to Present at the 29th Annual Piper Jaffray Healthcare Conference
27/11/2017
DUBLIN, Ireland, Nov. 27, 2017 (GLOBE NEWSWIRE) -- Avadel Pharmaceuticals plc (NASDAQ: AVDL ), today announced that Mike Kanan, Chief Financial Officer, and Lauren Stival, Senior Director, Investor Relations, will [...]
TG Therapeutics Announces Initiation of National Cancer Institute/SWOG-Sponsored Randomized Phase II Trial in Follicular Lymphoma
27/11/2017
NEW YORK, Nov. 27, 2017 (GLOBE NEWSWIRE) -- TG Therapeutics (NASDAQ: TGTX ) announced today that along with SWOG, the global cancer clinical trials group funded by the National Cancer Institute (NCI), it has initiated a [...]
Forward Pharma to Participate in Investor Conferences in December
27/11/2017
COPENHAGEN, Denmark, Nov. 27, 2017 (GLOBE NEWSWIRE) -- Forward Pharma A/S (NASDAQ: FWP ) (the “Company”) today announced that Dr. Claus Bo Svendsen, the Company’s Chief Executive Officer, will participate in two [...]
The Joint Corp. to Present at the 6th Annual Roth Utah Active & Healthy Lifestyle Corp Access Event
27/11/2017
SCOTTSDALE, Ariz., Nov. 27, 2017 (GLOBE NEWSWIRE) -- The Joint Corp. (NASDAQ: JYNT ), a national operator, manager and franchisor of chiropractic clinics, announced it will conduct one-on-one meetings at the 6 th Annual [...]
Intercept Pharmaceuticals Appoints Christian Weyer as Executive Vice President of Research & Development
27/11/2017
NEW YORK, Nov. 27, 2017 (GLOBE NEWSWIRE) -- Intercept Pharmaceuticals, Inc. (Nasdaq: ICPT ), a biopharmaceutical company focused on the development and commercialization of novel therapeutics to treat progressive non- [...]
Protalix BioTherapeutics Presents Positive Results from the Phase I/II Open-Label Extension Trial for PRX-102 at the New Horizons for Fabry Disease Conference
27/11/2017
Continued to Demonstrate Improvement across all Key Fabry Disease Parameters at 24 Months Low Incidence of Treatment Induced Anti-Drug Antibodies which Reversed Entirely Following 12 Months of Treatment without [...]

Pages